If Federal Transit Funding Falls Short, Will the Private Sector Fill the Gaps?

 

 Key Points:

  • A lack of a dedicated funding as well as additional expansion over the years has given Metrorail problems.
  • Transit agencies have been relying on special equipment made only by a few US companies.
  • Technical support from manufactures as well as organized safety culture that includes procedures for employees to follow are needed in order to improve the process.

Commentary:

The US’ urban centers continue to explode in population size decade after decade, and with more people comes more traffic. Many cities either rely heavily on public transit or try to incentivize the use of it to cut down on congestion. In D.C, for example, the rail and bus system serves a population of four million passengers. Recently, D.C. commuters have faced delays after Metrorail decommissioned nearly 60 percent of its rail fleet to investigate a derailment, which the Safety Commission attributed to a defective axle. MarketScale contacted Matt Dean, graduate student at the Cockrell School of Engineering at the University of Texas to give his assessment on if this reflects the net effect of municipalities’ investments, or disinvestments, in public transit over the years.

Abridged Thoughts:

If Metrorail or other agencies can’t create a safe, resilient system, then it’s no surprise riders will look elsewhere, and so private sector ride hail companies may attract customers in the short term. Prices will rise as taxi companies wane and investors look for profits after years of subsidizing growth in this market. Since road space is limited, the growth of ride hail companies is limited to passengers’ willingness to sit-in traffic. And if public transit can’t safely provide cost effective service for the masses, then they may have to adopt innovative partnerships with the private sector. Of course, there’s a lot of competition right now in the mobility space, and the public should expect the sort of blurring of the lines between public transit and private companies in the years to come.

More Stories Like This:

Trucks Move 72% of Our Goods, Will Infrastructure Capacity Force This to Shift?

Education, Not Money, Will Build the Future of America’s Infrastructure

Follow us on social media for the latest updates in B2B!

Image

Latest

Doable
Rethinking Leadership: Why “Doable” Might Be the Most Powerful Strategy in Education Today
April 3, 2026

At a time when educator burnout is rising and schools across the U.S. are facing ongoing teacher shortages, leaders are being forced to rethink what sustainable success actually looks like. Research shows that teacher attrition is closely tied to working conditions, job-related stress, and workload demands. As districts push for innovation, data-driven instruction, and…

Read More
Casey Brown
From Poverty to Pricing Power | Why Great Companies Undercharge
April 2, 2026

Casey Brown didn’t grow up thinking she would become an entrepreneur. She grew up in a blue-collar family where money was always tight — close enough to the edge that the fear of poverty shaped many of her early decisions. That fear led her into engineering, into corporate America, and eventually into a moment…

Read More
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
April 2, 2026

In this episode of Care Anywhere, host Lea Sims sits down with Nigerian nurse entrepreneur and advocate Obafemi Arowosegbe to discuss leadership, mentorship, and the future of nursing in Africa. While still a nursing student, Obafemi founded the Nightingale Summit, a growing conference designed to empower nursing students and early-career nurses with leadership skills,…

Read More
Oncology
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation
April 1, 2026

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Read More